Objective: Sera of Hashimoto's thyroiditis (HT) patients are known to exhibit elevated levels of anti-thyroglobulin IgG (TgAb IgG). Therefore, TgAb IgG represents a hallmark of this debilitating autoimmune disease. The aim of our study was to investigate the differential expression of specific glycosylation patterns of TgAb IgG from HT patients and healthy blood donors.
Methods: HT patients (n = 32) were divided into two subgroups, medium level group (mHT, n = 15) and high level group (hHT, n = 17), according to the serum levels of TgAb detected by electrochemiluminescence immunoassay. TgAb IgG was purified by affinity chromatography from the sera of the HT group and control group (n = 15). MALDI-QIT-TOF-MS/MS spectrometry was performed to identify the glycosylation profiles of purified TgAb IgG. Lectin microarray technology was used to compare the abundance of different glycans found on TgAb IgG between HT patients and controls, and between the mHT and hHT groups.
Results: The results by MALDI-QIT-TOF-MS/MS showed that the glycosylation profiles of TgAb IgG were similar between the mHT, hHT, and control groups. Furthermore, the lectin microarray showed that compared to the control group (all P < .001), there were higher levels present of (1) mannose (detected as lectin LCA, VFA, and MNA-M); (2) terminal sialic acid (detected as SNA-I and PSA); (3) core fucose (detected as LcH); and (4) Gal(β1-4)GlcNAc(β1-2)Man glycans (detected as PHA-L) on TgAb IgG from the HT group. A similar trend was observed between the hHT and mHT group, with elevated levels of mannose, terminal sialic acid, core fucose, and Gal(β1-4)GlcNAc(β1-2)Man glycans on TgAb IgG found in the hHT group compared with the mHT group (all P < .05).
Conclusions: TgAb IgG of HT patients exhibits higher glycosylation levels than those observed for TgAb IgG of healthy controls. Our results provide new clues for exploring the role of TgAb in the pathogenesis of HT.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318900 | PMC |
http://dx.doi.org/10.1210/jc.2014-2921 | DOI Listing |
Arthritis Res Ther
January 2025
Scientific Research Project Department, Guangdong Artificial Intelligence and Digital Economy Laboratory (Guangzhou), Pazhou Lab, Guangzhou, China.
Eur Thyroid J
October 2024
Department of Endocrinology, Peking University First Hospital, Xicheng District, Beijing, China.
Background: To explore whether IgG4 is involved in the pathogenesis of IgG4 HT.
Methods: Serum TgAb IgG4 and TPOAb IgG4 were measured in IgG4 HT and non-IgG4 HT. C1q, mannose-binding lectin (MBL), Bb, C3d, C4d, and membrane attack complex (MAC) in thyroid tissues from IgG4 HT, non-IgG4 HT, and controls were examined by immunohistochemistry.
Cell Immunol
September 2024
Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Weihui City, Xinxiang City, Henan Province 453100, China.
Int Arch Allergy Immunol
December 2024
Department of Pain, The First People's Hospital of Yunnan Province, Kunming, China.
Introduction: Rheumatoid arthritis (RA) combined with hashimoto thyroiditis (HT) is an important cause of various fatal comorbidities of RA. There is no precise conclusion about the cause of this disease.
Methods: Peripheral blood and synovial tissue were collected from healthy participants, patients with RA, and patients with both RA and HT.
Int Immunopharmacol
August 2023
Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, PR China; NHC Key Laboratory of Etiology and Epidemiology, Harbin Medical University, Harbin 150081, PR China. Electronic address:
Background: Immune checkpoint inhibitors evoke the immune system, which may cause immune-related adverse effects. The predictors and mechanisms of anti-PD-1-associated thyroid immune injury remain unclear.
Methods: A retrospective analysis is conducted on 518 patients treated with anti PD-1/PD-L1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!